Mereo BioPharma Group Stock Forecast, Price & News

-0.05 (-1.55 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume800,486 shs
Average Volume1.90 million shs
Market Capitalization$215.58 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MREO News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

Mereo BioPharma Group logo

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.18 out of 5 stars

Medical Sector

988th out of 2,096 stocks

Pharmaceutical Preparations Industry

486th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Mereo BioPharma Group (NASDAQ:MREO) Frequently Asked Questions

Is Mereo BioPharma Group a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mereo BioPharma Group stock.
View analyst ratings for Mereo BioPharma Group
or view top-rated stocks.

What stocks does MarketBeat like better than Mereo BioPharma Group?

Wall Street analysts have given Mereo BioPharma Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mereo BioPharma Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Mereo BioPharma Group's next earnings date?

Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 30th 2021.
View our earnings forecast for Mereo BioPharma Group

How has Mereo BioPharma Group's stock been impacted by Coronavirus (COVID-19)?

Mereo BioPharma Group's stock was trading at $1.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MREO shares have increased by 105.2% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MREO?

2 analysts have issued twelve-month price objectives for Mereo BioPharma Group's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Mereo BioPharma Group's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 214.5% from the stock's current price.
View analysts' price targets for Mereo BioPharma Group
or view top-rated stocks among Wall Street analysts.

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the following people:
  • Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 62, Pay $1.23M)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 52, Pay $898.21k)
  • Dr. Alastair MacKinnon MBBS, M.D., Co-Founder and Chief of Portfolio & Pipeline Strategy (Age 51, Pay $885.1k)
  • Mr. John Richard, Co-Founder & Chief Bus. Officer (Age 64, Pay $838.97k)
  • Dr. John A. Lewicki, Chief Scientific Officer (Age 69, Pay $793.37k)
  • Ms. Alexandra Hughes-Wilson, Chief of Patient Access & Commercial Planning (Age 50, Pay $508.3k)
  • Ms. Jill Henrich, US Site Head & Sr. VP of Regulatory Affairs (Age 58, Pay $430.25k)
  • Ms. Christine Fox CPA, Chief Financial Officer (Age 40)
  • Dr. Fiona Bor, Head of Intellectual Property
  • Mr. Ian Hodgson, Head of Clinical Operations

Who are some of Mereo BioPharma Group's key competitors?

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?

(MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (25.47%), Point72 Asset Management L.P. (12.21%), Baker BROS. Advisors LP (9.91%), Suvretta Capital Management LLC (9.39%), Perceptive Advisors LLC (8.85%) and Rock Springs Capital Management LP (6.63%).

Which institutional investors are selling Mereo BioPharma Group stock?

MREO stock was sold by a variety of institutional investors in the last quarter, including Holocene Advisors LP, Silverarc Capital Management LLC, Renaissance Technologies LLC, and CSS LLC IL.

Which institutional investors are buying Mereo BioPharma Group stock?

MREO stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Rock Springs Capital Management LP, Suvretta Capital Management LLC, Orbimed Advisors LLC, Millennium Management LLC, Endurant Capital Management LP, and Sphera Funds Management LTD..

How do I buy shares of Mereo BioPharma Group?

Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mereo BioPharma Group's stock price today?

One share of MREO stock can currently be purchased for approximately $3.18.

How much money does Mereo BioPharma Group make?

Mereo BioPharma Group has a market capitalization of $215.58 million. The company earns $-210,100,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does Mereo BioPharma Group have?

Mereo BioPharma Group employs 38 workers across the globe.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is

Where are Mereo BioPharma Group's headquarters?

Mereo BioPharma Group is headquartered at ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company can be reached via phone at 44-33-3023-7300 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.